HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule

This article was originally published in The Tan Sheet

Executive Summary

Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule

You may also be interested in...



FDA Generics Rule: Relevance To Pending NDAs May Need Clarification – Troy

Patent information in currently pending NDAs may not fall under the jurisdiction of FDA's final rule on generic drugs

FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing

FDA's final rule to reform Hatch/Waxman requires an innovator company to test data to establish that a polymorph claimed in a patent is the same as the active ingredient in the NDA

Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings

A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity

Related Content

Topics

UsernamePublicRestriction

Register

RS128832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel